EN DE
STOCK COMPARISON

Wockhardt vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Wockhardt (532300) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 18, 2026.

As of Aug 18, 2026, Fair Value Calculator sees Wockhardt as the more attractively valued of the two: Wockhardt trades at ₹1,894 versus a fair value of ₹2,120 (+12%), while Jiangsu Hengrui Medicine Co trades at ¥52.87 versus ¥25.94 (-51%).
Wockhardt
532300.BSE · INR · Health Care
+12%
upside to fair value
undervalued
Price₹1,894
Fair Value₹2,120
Quality48/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-51%
upside to fair value
overvalued
Price¥52.87
Fair Value¥25.94
Quality66/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

WockhardtJiangsu Hengrui Medicine Co
Valuation
—P/E (TTM)43.6×
—P/S (TTM)10.84×
—P/B5.76×
—EV/EBITDA33.0×
—PEG0.93×
0.1%Dividend yield0.4%
—Dividend per share¥0.20
Profitability
0%Net margin25%
0%Operating margin32%
—Return on equity15%
0%Return on assets9%
Growth
0%Revenue growth (YoY)13%
7.8%Avg. growth/yr (3Y)13.9%
4.1%Avg. growth/yr (5Y)2.5%
Balance & size
0.31×Debt / equity—
$299MMarket cap$52B
expensiveGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 1 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Wockhardtof which business quality 44 · market factors 54 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 43
ProfitabilityMargins and returns on capital today
32
63
Quality GrowthAre margins and returns improving?
56
41
CashflowEarnings quality: real cash, not paper profit
39
82
Fin. StrengthBalance sheet, leverage, solvency risk
39
100
InvestmentDisciplined investing over empire-building
54
27
Low VolatilityCalm price path (market factor)
22
79
MomentumPrice trend over the last 3–12 months (market factor)
71
33
52W MomentumDistance to the 52-week high (market factor)
59
21
Net IssuanceBuybacks instead of dilution
60
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Wockhardt

DCF Models₹1,527
Earnings-Based₹1,648
Dividend Discount₹16.72
Multiples₹2,866
Asset-Based₹2,200
Economic Profit₹1,953
Growth Earnings₹2,377

9 of 20 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Wockhardt
Bear ₹1,664Fair Value ₹2,120Bull ₹2,540
₹1,894 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥32.81
¥52.87 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Wockhardt · Health Care

Quality score48 · below median
Fair value upside+12% · Top 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-51% · below median

Bottom line

As of Aug 18, 2026, Fair Value Calculator sees Wockhardt as the more attractively valued of the two: Wockhardt trades at ₹1,894 versus a fair value of ₹2,120 (+12%), while Jiangsu Hengrui Medicine Co trades at ¥52.87 versus ¥25.94 (-51%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
Wockhardt · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Wockhardt

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.